title: Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected].
abstract: We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasminogen activator and streptokinase. We occluded the middle cerebral arteries of 137 rabbits with radiolabeled blood clots and administered tissue plasminogen activator (n = 49), streptokinase (n = 40), or saline (n = 48) at various times after embolization. We assessed the rate of thrombolysis and cerebral hemorrhage 24 hours later. Both drugs were very effective in producing thrombolysis. Compared with saline, streptokinase caused a significant increase in the rate of cerebral hemorrhage (p less than 0.05), but tissue plasminogen activator did not. We conclude that thrombolytic therapy for acute stroke should be safer with tissue plasminogen activator than with streptokinase.
authors.affiliation: Department of Neurology, Veterans Administration Medical Center, San Diego, CA 92161.
authors.forename: P D
authors.initials: PD
authors.lastname: Lyden
authors.forename: K P
authors.initials: KP
authors.lastname: Madden
authors.forename: W M
authors.initials: WM
authors.lastname: Clark
authors.forename: K C
authors.initials: KC
authors.lastname: Sasse
authors.forename: J A
authors.initials: JA
authors.lastname: Zivin
mesh_terms: D000818:Animals; D002543:Cerebral Hemorrhage / Q000209:etiology* / Q000503:physiopathology; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004195:Disease Models, Animal; D002542:Intracranial Embolism and Thrombosis / Q000503:physiopathology; D008297:Male; D011817:Rabbits; D012307:Risk Factors; D013300:Streptokinase / Q000009:adverse effects* / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D013300:Streptokinase; D010959:Tissue Plasminogen Activator